← SynDRA
PF-05089771
SynDRA canonical compound SYN0036676 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | SCN9A |
|---|
| Mechanism of action | sodium channel blocker |
|---|
All known targets
Mechanisms of action (all sources)
- SCN9A BLOCKER
- Sodium channel protein type IX alpha subunit blocker
- SCN9A MODULATOR
- sodium channel blocker
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CYP2C9
- CYP3A4
- SCN10A
- SCN1A
- SCN2A
- SCN3A
- SCN4A
- SCN5A
- SCN7A
- SCN8A
- SLC22A12
- SLCO1B1
- SLCO1B3
- SLCO2B1
Cross-references
Synonyms
- Nav1.7 blockers (pain), Pfizer
- SCN9A blockers (pain), Pfizer/Icagen/Birkbeck
- Voltage-gated sodium channel 1.7 blockers (pain), Pfizer
- RefChem:172240
- DTXCID301766189
- C18H12Cl2FN5O3S2
- ZYSCOUXLBXGGIM-UHFFFAOYSA-N
- orb1299763
- SCHEMBL1095065
- SCHEMBL25819004
- SCHEMBL29376793
- SCHEMBL31060533
- UNII-25U4N985O2
- GTPL10723
- EX-A3401
- KZB40362
- MFCD28900736
- AKOS027324308
- CS-4194
- EBC-499094
- AC-33663
- BS-14697
- DA-66601
- HY-12883
- DB-412092
- PF5089771
- PF05089771
- C92497
- F85168
- PF 05089771?
- T70
- PF-05089771 p-toluene sulfonate
- MFCD30146405
- EBC-2079075
- AKOS027470316
- C25H20Cl2FN5O6S3
- CS-0021364
- HY-12883B
Look up PF-05089771 in the interactive SynDRA portal →